Analyst Stephen Baxter from Wells Fargo maintained a Buy rating on Oscar Health (OSCR – Research Report) and keeping the price target at $20.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Stephen Baxter has given his Buy rating due to a combination of factors which include the company’s promising 2025 guidance and its strategic handling of payment integrity issues. Despite a higher Medical Loss Ratio (MLR) in the fourth quarter, driven by risk adjustment true-ups, Oscar Health’s revenue and adjusted EBITDA projections for 2025 are viewed as constructive, particularly against concerns over payment integrity.
Furthermore, the company’s expected revenue growth of 22.6% year-on-year and its adjusted operating income guidance provide a solid foundation for future profitability. While the market’s reaction to the recent results was negative, Baxter considers these concerns overdone, as the key issues are being addressed with conservative assumptions around potential risks. These steps towards stabilization and growth underpin the Buy rating for Oscar Health.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OSCR in relation to earlier this year.